Not Your Average Knockout: Introducing Cell Editing with XDel CRISPR Technology

Disease Models, iPS Cells, Immortalized Cell Lines | January 28, 2025 | By Amalia Soenens
Not Your Average Knockout: Introducing Cell Editing with XDel CRISPR Technology
Share

Order XDel knockout cells

Order Now
What You Missed at AACR 2026: Five Takeaways From San Diego That Could Change Your Cell Lineup
Drug Discovery

What You Missed at AACR 2026: Five Takeaways From San Diego That Could Change Your Cell Lineup

A field report from the EditCo team

Read More
Ensuring iPSC Quality: Best Practices in Pluripotency Testing for Disease Models
iPS Cells

Ensuring iPSC Quality: Best Practices in Pluripotency Testing for Disease Models

As iPSC disease models become increasingly sophisticated through CRISPR genome editing, organoid development, and single-cell analysis, comprehensive iPSC quality control now extends beyond pluripotency markers alone. Researchers increasingly evaluate pluripotency, genomic stability, and lineage-specific differentiation potential as part of a broader validation strategy. Introduction The power of human induced pluripotent stem cells (iPSCs) lies in their ability to self-renew indefinitely and differentiate into any cell type of the human body. These properties make iPSCs indispensable for disease modelling, drug discovery, regenerative medicine, and cell-therapy development. However, the “pluripotent” label comes with a critical caveat: without rigorous testing of pluripotency (identity, potency, functionality), downstream experiments and therapies risk yielding unreliable or unsafe results. In this article, we explore the spectrum of methods for assessing pluripotency in iPSCs, compare their advantages and limitations, and highlight how implementing robust testing workflows can safeguard the quality of your iPSC-derived models and therapeutic products. Download iPS Cells tech note : Precision CRISPR Editing of Induced Pluripotent Stem (iPS) Cells

Read More
EditCo Bio & Promega Partner to Advance Cell-Based Research
Knock-in

EditCo Bio & Promega Partner to Advance Cell-Based Research

EditCo’s robust, HiBiT-tagged CRISPR knock-ins transform cells into powerful biosensors — perfect for drug discovery, cell-based assays, and protein quantification. Through this partnership, EditCo Bio expands its capabilities by incorporating Promega’s proprietary bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines, ensuring precise gene edits with functional validation.

Read More